Cargando…

Safety and Immunogenicity Following Administration of a Live, Attenuated Monovalent 2009 H1N1 Influenza Vaccine to Children and Adults in Two Randomized Controlled Trials

BACKGROUND: The safety, tolerability, and immunogenicity of a monovalent intranasal 2009 A/H1N1 live attenuated influenza vaccine (LAIV) were evaluated in children and adults. METHODS/PRINCIPAL FINDINGS: Two randomized, double-blind, placebo-controlled studies were completed in children (2–17 y) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mallory, Raburn M., Malkin, Elissa, Ambrose, Christopher S., Bellamy, Terramika, Shi, Li, Yi, Tingting, Jones, Taff, Kemble, George, Dubovsky, Filip
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966412/ https://www.ncbi.nlm.nih.gov/pubmed/21060780 http://dx.doi.org/10.1371/journal.pone.0013755

Ejemplares similares

Live-Attenuated Influenza Vaccine Effectiveness in Children From 2009 to 2015–2016: A Systematic Review and Meta-Analysis
por: Caspard, Herve, et al.
Publicado: (2017)

Letter to the editor: Potential causes of the decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines
por: Ambrose, Christopher S, et al.
Publicado: (2016)

Concomitant administration of seasonal trivalent and pandemic monovalent H1N1 live attenuated influenza vaccines
por: Woo, Jennifer C., et al.
Publicado: (2009)

Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow‐fill‐seal device in adults: a randomized, active‐controlled study
por: Sheldon, Eric A., et al.
Publicado: (2012)

1954. A Randomized Study to Evaluate the Shedding and Immunogenicity of H1N1 Strains in Trivalent and Quadrivalent Formulations of FluMist in Children 24 to <48 Months of Age
por: Mallory, Raburn, et al.
Publicado: (2018)

1401. Real-World Effectiveness of Inactivated and Live Attenuated Influenza Vaccines in Children During Three Recent Seasons: 2016–2019
por: Bandell, Allyn, et al.
Publicado: (2020)

Immunogenicity and Reactogenicity of 2009 Influenza A (H1N1) Inactivated Monovalent Non-Adjuvanted Vaccine in Elderly and Immunocompromised Patients
por: Miraglia, João L., et al.
Publicado: (2011)

The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2‐18 years: Results of two phase 3 studies
por: Mallory, Raburn M., et al.
Publicado: (2018)

Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants: randomized, observer-masked, single-center clinical study
por: Wang, Shilei, et al.
Publicado: (2014)

Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink
por: Caspard, Herve, et al.
Publicado: (2018)

Comparative analysis of the immunogenicity of monovalent and multivalent rotavirus immunogens
por: Mi, Kai, et al.
Publicado: (2017)

Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age
por: Malkin, Elissa, et al.
Publicado: (2013)

Immunogenicity of a Monovalent 2009 Influenza A (H1N1) Vaccine Among Pregnant Women: Lowered Antibody Response by Prior Seasonal Vaccination
por: Ohfuji, Satoko, et al.
Publicado: (2011)

Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9)
por: Sobhanie, Mahdee, et al.
Publicado: (2016)

1973. A Meta-Analysis of the Effectiveness of LAIV4 and IIV against Influenza A/H3N2 Strains in Children 2–18 Years of Age During the 2016–2017 Season
por: Mallory, Raburn, et al.
Publicado: (2018)

Assessment of epicutaneous testing of a monovalent Influenza A (H1N1) 2009 vaccine in egg allergic patients
por: Pitt, Tracy, et al.
Publicado: (2011)

An analysis of national target groups for monovalent 2009 pandemic influenza vaccine and trivalent seasonal influenza vaccines in 2009-10 and 2010-11
por: Ng, Sophia, et al.
Publicado: (2011)

2337. Immunogenicity and Safety of a Heterologous Booster Dose of Omicron Subvariant (BA.1 and BA.5) and Bivalent SARS-CoV-2 Recombinant Spike Protein Vaccines: A Phase 3, Randomized, Clinical Trial
por: Bennett, Chijioke, et al.
Publicado: (2023)

Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

Adverse Events Following Pandemic A (H1N1) 2009 Monovalent Vaccines in Pregnant Women — Taiwan, November 2009–August 2010
por: Huang, Wan-Ting, et al.
Publicado: (2011)

Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6–35 months: a randomized, double‐blind, controlled phase I clinical trial
por: Li, Yan‐Ping, et al.
Publicado: (2012)

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant
por: Chen, Wilbur H., et al.
Publicado: (2014)

Safety of Pandemic (H1N1) 2009 Monovalent Vaccines in Taiwan: A Self-Controlled Case Series Study
por: Huang, Wan-Ting, et al.
Publicado: (2013)

Assessing the immunogenicity of an inactivated monovalent vaccine in the endangered African wild dog (Lycaon pictus)
por: Anderson, Nicole, et al.
Publicado: (2019)

Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial
por: Wood, Nicholas, et al.
Publicado: (2018)

Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen
por: Sakhatskyy, Pavlo, et al.
Publicado: (2006)

Immunogenicity of Reduced-Dose Monovalent Type 2 Oral Poliovirus Vaccine in Mocuba, Mozambique
por: de Deus, Nilsa, et al.
Publicado: (2020)

Seroprevalence of Pandemic H1N1 Antibody among Health Care Workers in Hong Kong Following Receipt of Monovalent 2009 H1N1 Influenza Vaccine
por: Zhou, Ying, et al.
Publicado: (2011)

The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study
por: Van Damme, Pierre, et al.
Publicado: (2019)

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial
por: Formica, Neil, et al.
Publicado: (2021)

Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC® and ROTAVAC 5D® in Zambian infants
por: Chilengi, R., et al.
Publicado: (2021)

Determinants of Vaccine Immunogenicity in HIV-Infected Pregnant Women: Analysis of B and T Cell Responses to Pandemic H1N1 Monovalent Vaccine
por: Weinberg, Adriana, et al.
Publicado: (2015)

Meta-Analysis of the Immunogenicity and Tolerability of Pandemic Influenza A 2009 (H1N1) Vaccines
por: Manzoli, Lamberto, et al.
Publicado: (2011)

CD4(+) T-Cell Expansion Predicts Neutralizing Antibody Responses to Monovalent, Inactivated 2009 Pandemic Influenza A(H1N1) Virus Subtype H1N1 Vaccine
por: Nayak, Jennifer L., et al.
Publicado: (2013)

Association between monovalent influenza A (H1N1) pdm09 vaccine and pneumonia among the elderly in the 2009–2010 season in Japan: A case-control study
por: Kondo, Kyoko, et al.
Publicado: (2015)

The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing
por: Ambrose, C. S., et al.
Publicado: (2012)

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old
por: Keitel, Wendy A., et al.
Publicado: (2015)

XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
por: Patel, Nita, et al.
Publicado: (2023)

Effect of monovalency on anti-contactin-1 IgG4
por: Taieb, Guillaume, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qgbd5n15hpt9q7h5igtnlfhi5v